Last reviewed · How we verify
Bupivacaine with Epinephrine
At a glance
| Generic name | Bupivacaine with Epinephrine |
|---|---|
| Also known as | Marcaine, Exparel, Sensorcaine, Marcaine, Sensorcaine, Sensorcaine/Epinephrine, Sensorcaine-MPF/Epinephrine, Marcaine-Epinephrine (PF) |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block (NA)
- Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition (PHASE4)
- Postop Pain Management in Pituitary Tumour Patients (PHASE4)
- Prospective Evaluation of Efficacy of Tumescent Steroid Infiltration in Mandibular Third Molar Surgery: a Split Mouth Randomized Study (NA)
- Local Anesthesia for Facial Fractures (PHASE2)
- Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty (PHASE4)
- Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine with Epinephrine CI brief — competitive landscape report
- Bupivacaine with Epinephrine updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI